Respiratory tract infections (RTIs) have been critically associated with health care problems globally. Subsequently, increased antibiotic resistance rates have limited treatment options that are further exaggerated due to lack of newer novel drugs and therapies. Current study highlights, antibiotic resistance profiling along with extended-spectrum beta-lactamase (ESBL) producers of RTI pathogens from Bengaluru. During June 2020-May 2021, 1016 clinical samples collected, prevalence rate of 22.4% was exhibited, with highest in male (74.5%). Following age group, 30-35 years displayed highest (24.1%) though, lowest was in 45-50 years (1.3%). The standard microbiological characterization revealed Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii as predominant bacterial pathogens associated with RTIs. While, Antibiotic susceptibility test (AST) exhibited highest resistance rates for different antibiotics in the following pathogens, as K. pneumoniae for ampicillin (74.8%), P. aeruginosa for doripenem (66.6%), A baumannii to piperacillin/tazobactam (76.9%), E. coli for penicillin and β-lactamase inhibitors ranging between 56-92%, E. cloacae to ticarcillin/clavulanic acid besides cefuroxime (100%). However, prevalence of Gram-positive strains were lowest and exhibited highest resistance to penicillin, and fluoroquinolone (83.3%). ESBL producers were predominantly K. pneumoniae, followed by E. coli, and E. cloacae with 21.9%, 6.5% and 1.3%, respectively. Notably, all the Gram-negative strains showed 100% sensitivity towards colistin with remarkable sensitivity was observed in oxazolidinone, glycopeptides by S. aureus and Coagulase-neagtive Staphylococcus aureus (CoNS). The study emphasizes increased antimicrobial resistance antimicrobial and ESBL resistance, suggesting AST as a systematic approach for apprising treatment guidelines in current scenario. The present study denotes polypeptide colistin as choice of drugs for treating RTI pathogens, however its not recommended in all cases.